[go: up one dir, main page]

ECSP19001438A - Anticuerpos anti_ige - Google Patents

Anticuerpos anti_ige

Info

Publication number
ECSP19001438A
ECSP19001438A ECSENADI20191438A ECDI201901438A ECSP19001438A EC SP19001438 A ECSP19001438 A EC SP19001438A EC SENADI20191438 A ECSENADI20191438 A EC SENADI20191438A EC DI201901438 A ECDI201901438 A EC DI201901438A EC SP19001438 A ECSP19001438 A EC SP19001438A
Authority
EC
Ecuador
Prior art keywords
ige
improved
antigen
binding agents
antibodies
Prior art date
Application number
ECSENADI20191438A
Other languages
English (en)
Inventor
Alistair James Henry
Brian John Sutton
Ralph Adams
Marta Katarzyna Westwood
James Michael Mcdonnell
Xiaofeng Liu
Thomas Allen Ceska
Anna Marie Davies
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of ECSP19001438A publication Critical patent/ECSP19001438A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)

Abstract

La presente invención se relaciona con el área de anti-cuerpos anti_IgE y agentes de unión a antígeno mejorados y sus composiciones dirigidos a IgE, por ejemplo: para su uso en el tratamiento de trastornos ocasionados por IgE (como por ejemplo respuestas alérgicas o ciertas respuestas autoinmunitarias); y, en particular, en trastornos ocasionados por la actuación recíproca de IgE con el receptor de FcεRI. En particular, esta invención se relaciona con anticuerpos anti_IgE y agentes de unión a antígeno mejorados relacionados con mutantes novedosos de omalizumab (Xolair®). Los anticuerpos anti_IgE y agentes de unión a antígeno mejorados de la invención pueden tener una afinidad mejorada para IgE y/o una actuación recíproca mejorada con el dominio Cε2 de IgE y/o un epítopo modi-ficado mejorado en IgE (por ejemplo en el cual participa adicionalmente el dominio Cε2 de IgE) y/o la capacidad para disociar IgE del receptor de FcεRI por ejemplo a concentraciones relevantes desde el punto de vista farma-céutico. En un aspecto, se revelan tratamientos mejorados o novedosos para trastornos mediados por IgE en los cuales IgE es seleccionada como meta (por ejemplo IgE libre y/o IgE en un complejo con el receptor de FcεRI).
ECSENADI20191438A 2016-06-10 2019-01-08 Anticuerpos anti_ige ECSP19001438A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1610198.2A GB201610198D0 (en) 2016-06-10 2016-06-10 Anti-ige antibodies
GBGB1702435.7A GB201702435D0 (en) 2016-06-10 2017-02-15 Anti-ige antibodies

Publications (1)

Publication Number Publication Date
ECSP19001438A true ECSP19001438A (es) 2019-01-31

Family

ID=56894897

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI20191438A ECSP19001438A (es) 2016-06-10 2019-01-08 Anticuerpos anti_ige

Country Status (26)

Country Link
US (3) US11214627B2 (es)
EP (1) EP3468995A1 (es)
JP (3) JP7164439B2 (es)
KR (1) KR102456813B1 (es)
CN (1) CN109379892B (es)
AR (1) AR108707A1 (es)
AU (1) AU2017277600B2 (es)
BR (1) BR112018074838A2 (es)
CA (1) CA3027120A1 (es)
CL (2) CL2018003556A1 (es)
CO (1) CO2018013006A2 (es)
EA (1) EA201990004A1 (es)
EC (1) ECSP19001438A (es)
GB (2) GB201610198D0 (es)
IL (3) IL309516A (es)
MA (1) MA45231A (es)
MX (1) MX2018014761A (es)
PE (1) PE20190212A1 (es)
PH (1) PH12018502574A1 (es)
SG (1) SG11201810199WA (es)
TN (1) TN2018000423A1 (es)
TW (1) TW201802114A (es)
UA (1) UA126468C2 (es)
UY (1) UY37290A (es)
WO (1) WO2017211928A1 (es)
ZA (2) ZA201807822B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201610198D0 (en) * 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
HUE065861T2 (hu) * 2016-08-26 2024-06-28 Sanofi Sa Szelektív könnyûlánc-párosítást elõsegítõ multispecifikus antitestek
EP3558363A1 (en) 2016-12-21 2019-10-30 Amgen Inc. Anti-tnf alpha antibody formulations
US20210115156A1 (en) 2018-04-13 2021-04-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Fc-engineered anti-human ige antibodies and methods of use
AR117653A1 (es) * 2018-10-16 2021-08-25 UCB Biopharma SRL Método para tratamiento de miastenia grave
GB2589049C (en) * 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies
CA3146381A1 (en) * 2019-07-11 2021-01-14 Wuhan Yzy Biopharma Co., Ltd. Tetravalent symmetric bispecific antibodies
AU2020356620A1 (en) 2019-09-25 2022-04-28 Massachusetts Institute Of Technology Therapeutic neutralization antibodies for the treatment of peanut allergy
AU2020358898B2 (en) * 2019-10-01 2025-10-16 Epsilogen Ltd Hybrid antibody
TW202128748A (zh) 2020-01-24 2021-08-01 日商西斯美股份有限公司 提升抗體對抗原之親和性的方法及其用途
CN113372450A (zh) * 2020-03-10 2021-09-10 北京万华生物工程有限公司 IgE嵌合性双特异性抗体制备及应用
WO2021225980A1 (en) * 2020-05-04 2021-11-11 Dna-Seq, Inc. Methods and systems for determination of an effective therapeutic regimen and drug discovery
WO2021250546A1 (en) 2020-06-09 2021-12-16 University Of Washington Micrornas as predictors of response to anti-ige therapies in chronic spontaneous urticaria
CN111875706B (zh) * 2020-07-16 2021-03-30 广州康盛生物科技股份有限公司 一种抗人IgE蛋白的单域抗体及其应用
KR20220029524A (ko) * 2020-08-31 2022-03-08 (주)메디톡스 항-ｖｅｇｆ 육량체 항체, 및 이를 포함하는 조성물
WO2022061236A1 (en) * 2020-09-21 2022-03-24 The Board Of Trustees Of The Leland Stanford Junior University High affinity anti-ige antibodies
CN118119641A (zh) * 2021-10-12 2024-05-31 联合生物制药股份有限公司 Ige调节的疾病的治疗
WO2023070502A1 (zh) * 2021-10-29 2023-05-04 天辰生物医药(苏州)有限公司 分离的抗原结合蛋白及其用途
CN114028569B (zh) * 2021-12-20 2023-04-28 中国医学科学院基础医学研究所 免疫球蛋白IgE在诊断和/或治疗高血压中的用途
CN114504644B (zh) * 2021-12-24 2024-02-13 北京大学第一医院 抗IgE抗体在用于治疗腺样体肥大中的应用
KR20250042149A (ko) * 2022-07-01 2025-03-26 알크-아벨로 에이/에스 Ige-fceri의 디스플레이서
CN120271714A (zh) * 2022-12-07 2025-07-08 南开大学 一种针对IgE的抗体或其抗原结合片段以及Fc变体
CN118725128B (zh) * 2023-03-28 2025-09-16 东莞市朋志生物科技有限公司 抗IgE抗体、检测IgE的试剂和试剂盒
KR20240163406A (ko) 2023-05-10 2024-11-19 대한민국 (식품의약품안전처장) 아나필락시스 예측용 바이오마커
CN116754773B (zh) * 2023-05-15 2024-06-07 江南大学 一种免疫球蛋白e的检测试剂盒
CA3237624A1 (en) * 2023-07-28 2025-04-24 Genentech, Inc. NEW USES FOR OMALIZUMAB
CN119490595B (zh) * 2023-08-15 2025-11-18 东莞市朋志生物科技有限公司 一种抗免疫球蛋白e的抗体及其应用
WO2025122927A1 (en) * 2023-12-06 2025-06-12 Integral Molecular, Inc. Antibodies directed to claudin 18.2, including bispecific formats thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
US20250353928A1 (en) * 2024-05-17 2025-11-20 Excellergy, Inc. Antibodies and antibody fragments that bind ige
US12509529B2 (en) 2024-05-17 2025-12-30 Excellergy, Inc. Antibodies and antibody fragments that bind IgE
CN119841957B (zh) * 2025-01-13 2025-08-05 上海领检科技有限公司 一种抗人IgE抗体及其用途

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
EP1186660A3 (fr) 1985-03-30 2002-03-20 KAUFFMAN, Stuart A. Procédé d'obtension d'ADN, ARN, peptides, polypeptides ou protéines, par une technique de recombination d'ADN
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
WO1990014443A1 (en) 1989-05-16 1990-11-29 Huse William D Co-expression of heteromeric receptors
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0542810A1 (en) 1990-08-02 1993-05-26 B.R. Centre Limited Methods for the production of proteins with a desired function
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
EP0602126B1 (en) 1991-08-14 2003-03-05 Genentech, Inc. Immunoglobulin variants for specific fc epsilon receptors
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
EP0571613B1 (en) 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
ZA966075B (en) 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
PT1516628E (pt) 1995-07-27 2013-09-24 Genentech Inc Formulação de proteína liofilizada isotónica estável
ZA971607B (en) * 1996-03-12 1998-08-25 Univ Johns Hopkins Methods of treatment of allergic diseases
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
WO1999038531A1 (en) * 1998-01-29 1999-08-05 Tanox, Inc. TREATING ATOPIC DERMATITIS WITH IgE ANTAGONISTS
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
WO2000072879A1 (en) * 1999-05-26 2000-12-07 Tanox, Inc. TREATING ALLERGIC DISEASES WITH IMMUNOTHERAPY AND IgE ANTAGONISTS
CA2380443C (en) 2000-05-26 2013-03-12 Ginette Dubuc Single-domain antigen-binding antibody fragments derived from llama antibodies
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
US7993864B2 (en) 2002-12-03 2011-08-09 Ucb Pharma S.A. Assay for identifying antibody producing cells
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
PL1644412T5 (pl) 2003-07-01 2019-01-31 Ucb Biopharma Sprl Modyfikowane fragmenty Fab przeciwciała
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
GB0502358D0 (en) 2005-02-04 2005-03-16 Novartis Ag Organic compounds
RU2515108C2 (ru) 2005-08-19 2014-05-10 Эббви Инк Иммуноглобулин с двойными вариабельными доменами и его применения
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
SG182985A1 (en) * 2007-04-02 2012-08-30 Amgen Fremont Inc Anti-ige antibodies
EP2155238B1 (en) * 2007-06-05 2016-04-06 Yale University Antibody against d4 domain of the kit receptor and use thereor
CN101842387B (zh) 2007-09-26 2014-05-07 Ucb医药有限公司 双特异性抗体融合物
EP2604628A3 (en) 2007-12-21 2013-08-21 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4R) - 173
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
CN101230103B (zh) * 2008-03-25 2011-09-07 中国医药集团总公司四川抗菌素工业研究所 一全人源重组抗-IgE抗体
CA2737241C (en) 2008-09-26 2017-08-29 Ucb Pharma S.A. Multivalent antibody fusion proteins
ES2667258T3 (es) 2009-09-10 2018-05-10 Ucb Biopharma Sprl Anticuerpos multivalentes
NZ599600A (en) 2009-10-26 2015-04-24 Genentech Inc Assays for detecting antibodies specific to therapeutic anti-ige antibodies and their use in anaphylaxis
NZ607480A (en) 2010-08-03 2014-10-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
MX351502B (es) * 2011-11-11 2017-10-18 Ucb Pharma Sa Anticuerpos de union de albumina y fragmentos de union de los mismos.
AR091305A1 (es) 2012-01-31 2015-01-28 Genentech Inc ANTICUERPOS ANTI-IgE Y SUS METODOS DE USO
US20150140608A1 (en) 2012-06-01 2015-05-21 Momenta Pharmaceuticals, Inc. Methods related to omalizumab
JP6136279B2 (ja) 2013-01-15 2017-05-31 株式会社ジェイテクト 転がり軸受装置
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
US10196458B2 (en) * 2013-07-26 2019-02-05 The Regents Of The University Of California Anti-immunoglobulin E antibodies and methods of using thereof
TWI510996B (zh) 2013-10-03 2015-12-01 Acer Inc 控制觸控面板的方法以及使用該方法的可攜式電腦
CN104987412A (zh) 2015-07-14 2015-10-21 上海拜豪生物科技有限公司 一种砷-IgE螯合物及其制备方法和应用
US20180273626A1 (en) * 2015-09-11 2018-09-27 The Board Of Trustees Of The Leland Stanford Junio University Omalizumab resistant ige variants and their use in anti-ige therapy
GB201610198D0 (en) * 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor

Also Published As

Publication number Publication date
EP3468995A1 (en) 2019-04-17
TN2018000423A1 (en) 2020-06-15
AU2017277600B2 (en) 2024-08-29
EA201990004A1 (ru) 2019-06-28
GB201610198D0 (en) 2016-07-27
US11214627B2 (en) 2022-01-04
PE20190212A1 (es) 2019-02-07
JP2023021974A (ja) 2023-02-14
CN109379892A (zh) 2019-02-22
IL263452A (en) 2019-01-31
CL2021002696A1 (es) 2022-06-03
US20250011473A1 (en) 2025-01-09
JP7164439B2 (ja) 2022-11-01
AU2017277600A1 (en) 2019-01-03
CN109379892B (zh) 2023-07-04
CL2018003556A1 (es) 2019-04-05
CA3027120A1 (en) 2017-12-14
US20190144565A1 (en) 2019-05-16
IL309516A (en) 2024-02-01
CO2018013006A2 (es) 2019-04-30
IL263452B1 (en) 2024-01-01
JP7612641B2 (ja) 2025-01-14
AR108707A1 (es) 2018-09-19
AU2017277600A2 (en) 2019-01-17
TW201802114A (zh) 2018-01-16
RU2019100034A3 (es) 2020-11-20
MX2018014761A (es) 2019-04-25
MA45231A (fr) 2021-05-05
UY37290A (es) 2018-01-31
RU2019100034A (ru) 2020-07-13
GB201702435D0 (en) 2017-03-29
US20220235146A1 (en) 2022-07-28
JP2025011170A (ja) 2025-01-23
IL321493A (en) 2025-08-01
IL263452B2 (en) 2024-05-01
ZA201807822B (en) 2020-05-27
UA126468C2 (uk) 2022-10-12
BR112018074838A2 (pt) 2019-03-26
KR20190017949A (ko) 2019-02-20
PH12018502574A1 (en) 2019-10-28
WO2017211928A1 (en) 2017-12-14
US12054559B2 (en) 2024-08-06
SG11201810199WA (en) 2018-12-28
ZA202000803B (en) 2021-08-25
KR102456813B1 (ko) 2022-10-20
JP2019522470A (ja) 2019-08-15

Similar Documents

Publication Publication Date Title
ECSP19001438A (es) Anticuerpos anti_ige
CO2018004090A2 (es) Anticuerpos anti-tigit y métodos de uso
CO2018005932A2 (es) Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
MX2018001596A (es) Anticuerpos anti-receptor ccr7 humanizados.
EA201690325A1 (ru) БИСПЕЦИФИЧЕСКИЕ МОНОВАЛЕНТНЫЕ Fc-ДИАТЕЛА, КОТОРЫЕ СПОСОБНЫ СВЯЗЫВАТЬ CD32B И CD79b, И ИХ ПРИМЕНЕНИЯ
MX2019013132A (es) Anticuerpos que comprenden regiones constantes pesadas modificadas.
MX386942B (es) Anticuerpos que comprenden regiones constantes pesadas modificadas.
ECSP19029758A (es) Anticuerpos anti-il-33 y usos de los mismos
MX2018014172A (es) Métodos para romper la tolerancia inmunológica usando múltiples arn guías.
BR112018017172A2 (pt) anticorpos monoclonais anti-alfa-sinucleína para prevenção da agregação de tau
MX2019002344A (es) Metodos de prevenir o tratar la alergia administrando un antagonista de il-4r.
BR112022000328A2 (pt) Inibidores peptídicos do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias
BR112013021863A2 (pt) anticorpos anti-receptor il-6 e métodos de uso
BR112013007314A2 (pt) anticorpos anti-cd48 e seus usos
EA201791590A1 (ru) Антитела к tau и их применение
CL2023003695A1 (es) Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, métodos de uso
AR104250A1 (es) Anticuerpo anti-notch4 humano
ECSP19051912A (es) Estructura cristalina de gremlina 1 y anticuerpo inhibidor
MX2022011972A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
UY37089A (es) Moléculas con uso plaguicida, y sus intermediarios, composiciones y procesos relacionados
MX2018015265A (es) Metodos para el uso de moleculas de union a cd32b x cd79b en el tratamiento de enfermedades y trastornos inflamatorios.
CL2020000070A1 (es) Agentes, usos y métodos para el tratamiento.
GT201300058A (es) Composiciones de anticuerpos anti-vegfr-3
BR112019008776A2 (pt) composições, métodos e uso
CL2018003013A1 (es) Uso de un inhibidor de la acetilcolinesterasa e idalopirdina para reducir las caídas en pacientes con la enfermedad de parkinson.